[Etiology of bacterial pneumonias in patients with COVID-19]. 2022

Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
Instituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades, División de Medicina Preventiva y Epidemiología Hospitalaria. Ciudad de México, México.

Aggregate bacterial pneumonia plays a fundamental role in mortality of patients hospitalized with COVID-19. To estimate the association of aggregated bacterial pneumonia with mortality in patients at Hospital Especialidades "La Raza". Analytical cross-sectional study, 252 COVID-19 patients, chest x-ray and culture of bronchial secretion or expectoration. Data taken from the SIOC electronic file and the IZASAlab platform. 252 participants, positive culture, 89 patients, 35.3%, isolation of K. pneumoniae (22.5%), A. baumannii (20.2%), P. aeruginosa (13.5%) and S. aureus (11.2%), antimicrobial resistance 37.1%. 43.7% died, lung damage greater than 50% RMa 2.25 (95% CI 1.01-5.11) p=0.04 against minor lung damage; microorganism in culture RMa 9.04 (95% CI 3.06-26.74) p=0.000; antimicrobial resistance RMa 7.57 (95% CI 1.34-42.79) p=0.02; S. aureus RMa 1.24 (95% CI 0.36-4.23) p=0.73; A. baumannii RMa 3.74 (95% CI 1.41-9.91) p=0.008; K. pneumoniae RMa 4.12 (95% CI 1.55-10.97) p=0.005; and P. aeruginosa RMa 6.89 (95% CI 1.62-17.61) p=0.01. Uncontrolled Diabetes RMa 1.61 (IC95% 1.1-2.9) p=0.018. The development of added bacterial pneumonia increases the probability of death 2 times more, it amounts to 6 times more if there is antimicrobial resistance, it is observed to a greater extent for A. baumannii, K. pneumoniae and P. aeruginosa.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D018410 Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections. Bacterial Pneumonia,Bacterial Pneumonias,Pneumonias, Bacterial

Related Publications

Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
September 2021, Annals of the American Thoracic Society,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
January 1957, Tuberkuloza,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
January 1982, Revista clinica espanola,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
January 2005, Medicinski arhiv,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
August 2019, Seminars in respiratory and critical care medicine,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
July 1972, Vrachebnoe delo,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
October 2021, Current opinion in critical care,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
March 2022, Internal and emergency medicine,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
May 2023, Journal of the American Geriatrics Society,
Ulises Angeles-Garay, and Joel Alejandro Hernández-Herrera, and Jorge Procopio-Velázquez, and Julio Elías Alvarado-Yaah, and Isaac Leopoldo González-Cruz
May 1968, Sovetskaia meditsina,
Copied contents to your clipboard!